Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | MLYCD | O95822 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18880072 | 0.89 | ALDH1A1 (0.73) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL29221538 | 0.84 | TAAR1 (0.64) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL6029753 | 0.84 | KMT2A (0.58) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL8691196 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL178429 | 0.81 | MAPT (0.71) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL2608916 | 0.81 | MAPT (0.63) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL13390897 | 0.81 | KMT2A (0.63) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL2642376 | 0.79 | CA1 (0.62) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL10819622 | 0.79 | KMT2A (0.80) | ALDH1A1MAPTKMT2AMEN1RXFP1 | |
| SCHEMBL5227347 | 0.79 | ALDH1A1 (0.61) | ALDH1A1MAPTKMT2AMEN1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-08 | — | — | US | claimed |
| US-6583139-B1 | Treatment of inflammatory diseases; inflammatory brain diseases such as multiple sclerosis; N-(Toluene-4-sulfonyl)-L-prolyl-4-(alpha -methylbenzyloxy)-L-phenylalanine; Very Late Antigen 4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-06-24 | — | — | US | claimed |
| EP-0994896-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1999006437-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | claimed |
| EP-1038018-A4 | ALDOL CONDENSATIONS BY CATALYTIC ANTIBODIES | SCRIPPS RESEARCH INST (US) | 2004-10-13 | — | — | EP | disclosed |
| CN-1159299-C | Arylalkylpyridzinones | Ĭ��ר���ɷ�����˾ | 2004-07-28 | — | — | CN | disclosed |
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-08 | — | — | US | disclosed |
| US-6589766-B1 | Use to catalyze ketone-ketone, ketone-aldehyde, aldehyde-ketone, and aldehyde-aldehyde intermolecular aldol reactions, and in some cases to catalyze their subsequent dehydration to yield aldol condensation products | THE SCRIPPS RESEARCH INSTITUTE | 2003-07-08 | — | — | US | disclosed |
| US-6583139-B1 | Treatment of inflammatory diseases; inflammatory brain diseases such as multiple sclerosis; N-(Toluene-4-sulfonyl)-L-prolyl-4-(alpha -methylbenzyloxy)-L-phenylalanine; Very Late Antigen 4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-06-24 | — | — | US | disclosed |
| US-6531473-B2 | Phosphodiesterase inhibitor; antiinflammatory agents | MERCK PATENT GMBH (DE) | 2003-03-11 | — | — | US | disclosed |
| EP-0738715-B1 | Arylalkyl-pyridazinones | MERCK PATENT GMBH (DE) | 2003-01-29 | — | — | EP | disclosed |
| US-20020111356-A1 | Arylalkylpyridazinones | MERCK KGAA (DE) | 2002-08-15 | — | — | US | disclosed |
| US-6025354-A | Arylalkyl-thiadiazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-02-15 | — | — | US | disclosed |
| WO-1999031263-A1 | ALDOL CONDENSATIONS BY CATALYTIC ANTIBODIES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999006437-A1 | SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5747489-A | Arylalkyl-thiadiazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-05-05 | — | — | US | disclosed |
| CN-1146991-A | Arylalkyl-thiadiazinones | MERCK PATENT GMBH (DE) | 1997-04-09 | — | — | CN | disclosed |
| CN-1142493-A | Arylalkylpyridzinones | MERCK PATENT GMBH (DE) | 1997-02-12 | — | — | CN | disclosed |
| EP-0738715-A2 | Arylalkyl-pyridazinones | MERCK PATENT GmbH (DE) | 1996-10-23 | — | — | EP | disclosed |
| EP-0723962-A1 | Arylalkyl-thiadiazinones | MERCK PATENT GmbH (DE) | 1996-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | ALDH1A1 322/4885MAPT 816/4885KMT2A 1871/4885 |
| US-20020111356-A1 | Arylalkylpyridazinones | PDE4A, PDE5A, PDE2A | ALDH1A1 257/4885MAPT 4880/4885KMT2A 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.